JP5571168B2 - 抗癌剤ならびに悪性黒色腫および他の癌に関連する使用 - Google Patents

抗癌剤ならびに悪性黒色腫および他の癌に関連する使用 Download PDF

Info

Publication number
JP5571168B2
JP5571168B2 JP2012506649A JP2012506649A JP5571168B2 JP 5571168 B2 JP5571168 B2 JP 5571168B2 JP 2012506649 A JP2012506649 A JP 2012506649A JP 2012506649 A JP2012506649 A JP 2012506649A JP 5571168 B2 JP5571168 B2 JP 5571168B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
cancer
compound
diazenyl
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012506649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525329A (ja
JP2012525329A5 (enExample
Inventor
ゴカラジュ，ガンガ，ラジュ
カシナ，スダカー
ゴカラジュ，ラマ，ラジュ
ゴカラジュ，ベンカタ，カナカ，ランガ，ラジュ
サムパリ，ヴェンカテスワール
ゴラコチ，トリムーツル
ビューパチラジュ，キラン
セングプタ，クリシャヌ
アルリ，ベンカタ，クリシュナ，ラジュ
Original Assignee
カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド filed Critical カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド
Publication of JP2012525329A publication Critical patent/JP2012525329A/ja
Publication of JP2012525329A5 publication Critical patent/JP2012525329A5/ja
Application granted granted Critical
Publication of JP5571168B2 publication Critical patent/JP5571168B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
    • C07D517/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2012506649A 2009-04-27 2010-04-26 抗癌剤ならびに悪性黒色腫および他の癌に関連する使用 Expired - Fee Related JP5571168B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN959/CHE/2009 2009-04-27
IN959CH2009 2009-04-27
PCT/IN2010/000262 WO2010125575A1 (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Publications (3)

Publication Number Publication Date
JP2012525329A JP2012525329A (ja) 2012-10-22
JP2012525329A5 JP2012525329A5 (enExample) 2013-05-30
JP5571168B2 true JP5571168B2 (ja) 2014-08-13

Family

ID=42992332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506649A Expired - Fee Related JP5571168B2 (ja) 2009-04-27 2010-04-26 抗癌剤ならびに悪性黒色腫および他の癌に関連する使用

Country Status (11)

Country Link
US (1) US8143237B2 (enExample)
EP (1) EP2424351B1 (enExample)
JP (1) JP5571168B2 (enExample)
KR (1) KR20120006554A (enExample)
CN (1) CN102438449B (enExample)
AU (1) AU2010243213B2 (enExample)
BR (1) BRPI1006651A2 (enExample)
CA (1) CA2759519A1 (enExample)
IL (1) IL215789A0 (enExample)
NZ (1) NZ595602A (enExample)
WO (1) WO2010125575A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640392B1 (en) * 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
AU2011340063B2 (en) * 2010-12-09 2016-03-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012176212A1 (en) 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
EP2762472B1 (en) * 2011-09-28 2017-05-24 Industry-Academia Cooperation Group of Sejong University Selenophene-fused aromatic compound and manufacturing method thereof
KR101418776B1 (ko) 2011-09-28 2014-07-14 사회복지법인 삼성생명공익재단 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법
WO2014012000A2 (en) 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
WO2014012074A2 (en) 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
WO2014018888A1 (en) 2012-07-26 2014-01-30 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CN108129475A (zh) * 2018-02-08 2018-06-08 中南大学湘雅三医院 一种生物光敏剂及其制备方法和应用
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도
CN121712769A (zh) * 2023-06-29 2026-03-20 艾健科学股份有限公司 新型硒吩衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620804B2 (en) * 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
ATE247955T1 (de) * 1996-06-03 2003-09-15 Purdue Research Foundation Selenophen-antitumormittel
US20100183726A1 (en) 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions
BRPI0913485A2 (pt) * 2008-09-15 2016-06-07 Kasina Laila Innova Pharmaceuticals Private Ltd medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.

Also Published As

Publication number Publication date
NZ595602A (en) 2013-05-31
CA2759519A1 (en) 2010-11-04
IL215789A0 (en) 2012-01-31
BRPI1006651A2 (pt) 2015-08-25
US20100272678A1 (en) 2010-10-28
CN102438449B (zh) 2014-06-18
JP2012525329A (ja) 2012-10-22
US8143237B2 (en) 2012-03-27
AU2010243213B2 (en) 2014-09-11
HK1166591A1 (en) 2012-11-02
EP2424351B1 (en) 2015-10-21
AU2010243213A1 (en) 2011-10-27
WO2010125575A1 (en) 2010-11-04
EP2424351A1 (en) 2012-03-07
EP2424351A4 (en) 2013-04-03
CN102438449A (zh) 2012-05-02
KR20120006554A (ko) 2012-01-18

Similar Documents

Publication Publication Date Title
JP2012525329A (ja) 抗癌剤ならびに悪性黒色腫および他の癌に関連する使用
US8258119B2 (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CN103450077B (zh) IRE-1α抑制剂
El-Far et al. Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents
CN101663033B (zh) 作为smo拮抗剂的三唑衍生物
JP2013500255A (ja) 自食作用の強力な小分子阻害剤、およびそれの使用方法
PT2588457E (pt) Derivados de pirazoloquinolinas como inibidores de dna-pk
US8658664B2 (en) Cyclopamine tartrate salt and uses thereof
JP2014157014A (ja) 自己免疫疾患治療薬のスクリーニング方法
CN102724975A (zh) IRE-1α抑制剂
AU2015225828B2 (en) Mcl-1 modulating compounds for cancer treatment
JP2008542243A (ja) 新規のテトラヒドロピリドチオフェン
TW200403991A (en) NF-κb inhibitors
US9278958B2 (en) Anti-cancer compounds
JP2008530053A (ja) 癌の治療のための抗増殖性剤としてのテトラヒドロピリドチオフェン
CA2407755A1 (en) Inhibition of vegf secretion
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
HK1166591B (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
US20220332720A1 (en) Bicyclic agonists of stimulator of interferon genes sting
CN106117176B (zh) 二氢双苯并恶庚衍生物及其组合物与应用
CN121591767A (zh) 一种含有碳硼烷的化合物及其用途
JP2020536848A (ja) Ｉｌ−１２産生の刺激による癌の治療
HK1154863A (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140625

R150 Certificate of patent or registration of utility model

Ref document number: 5571168

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees